Gossamer Bio Files 8-K on Financials

TL;DR

Gossamer Bio dropped an 8-K on financials, check it for the latest numbers.

AI Summary

Gossamer Bio, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with no specific financial figures or operational details provided in this initial report.

Why It Matters

This 8-K filing indicates Gossamer Bio is providing an update on its financial condition and operational results to the SEC and investors.

Risk Assessment

Risk Level: low — This is a routine filing reporting on financial condition and operations, not indicating any immediate adverse events.

Key Players & Entities

• Gossamer Bio, Inc. (company) — Registrant
• May 15, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Offices

FAQ

From the Filing

0001728117-25-000037.txt : 20250515 0001728117-25-000037.hdr.sgml : 20250515 20250515160216 ACCESSION NUMBER: 0001728117-25-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250515 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 25952450 BUSINESS ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 684-1300 MAIL ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 goss-20250515.htm 8-K goss-20250515 0001728117 FALSE 0001728117 2025-05-15 2025-05-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter)   Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       3115 Merryfield Row, Suite 120 San Diego , California , 92121 (Address of Principal Executive Offices) (Zip Code) ( 858 ) 684-1300 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   GOSS   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 2.02 Results of Operations and Financial Condition. On May 15, 2025, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release attached as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into